Last reviewed · How we verify

Antipsychotic therapy — Competitive Intelligence Brief

Antipsychotic therapy (Antipsychotic therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic. Area: Neurology.

phase 1 Atypical antipsychotic Dopamine D2 receptor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Antipsychotic therapy (Antipsychotic therapy) — FORUM Pharmaceuticals Inc. Antagonizes dopamine D2 receptors

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Antipsychotic therapy TARGET Antipsychotic therapy FORUM Pharmaceuticals Inc phase 1 Atypical antipsychotic Dopamine D2 receptor
Abilify (aripiprazole) Abilify (aripiprazole) Genovate Biotechnology Co., Ltd., marketed Atypical antipsychotic Dopamine D2 receptor (partial agonist), Serotonin 5-HT1A receptor (partial agonist)
Quetiapine or Risperidone + Aripiprazole Quetiapine or Risperidone + Aripiprazole Otsuka Pharmaceutical Development & Commercialization, Inc. marketed Atypical antipsychotic Dopamine D2 receptor, serotonin 5-HT2A receptor
aripiprazole (Abilify) aripiprazole (Abilify) Massachusetts General Hospital marketed Atypical antipsychotic Dopamine D2 receptor (partial agonist), Serotonin 5-HT1A receptor (partial agonist)
Flupentixole Flupentixole Technical University of Munich marketed Antipsychotic Dopamine D2 receptors
Latuda (Lurasidone) Latuda (Lurasidone) Massachusetts General Hospital marketed Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT7 receptor
risperidone (Risperdal) risperidone (Risperdal) University of South Florida marketed Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT2A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic class)

  1. Shanghai Mental Health Center · 10 drugs in this class
  2. AstraZeneca · 6 drugs in this class
  3. Otsuka Pharmaceutical Development & Commercialization, Inc. · 5 drugs in this class
  4. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 4 drugs in this class
  5. Eli Lilly and Company · 4 drugs in this class
  6. Otsuka Pharmaceutical Co., Ltd. · 3 drugs in this class
  7. Medical University of Vienna · 2 drugs in this class
  8. Organon and Co · 2 drugs in this class
  9. Chengdu Kanghong Pharmaceutical Group Co., Ltd. · 2 drugs in this class
  10. H. Lundbeck A/S · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Antipsychotic therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/antipsychotic-therapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: